Seattle Genetics' fourth-quarter 2015 results were mixed, with the company missing bottom-line estimates but beating on revenues. Adcetris remains its growth engine. However, the guidance for Adcetris was quite disappointing. The company expects modest growth from the drug in 2016 which in turn will impact sales. Seattle Genetics' sole dependence on a single product for growth remains a matter of concern. On the bright side, company's collaborations with several leading health care companies like AbbVie, Bayer, Roche and Pfizer not only boost pipeline development, but also provide the company with funds in the form of upfront, milestone and other payments. Seattle Genetics is working on expanding Adcetris label which in turn would boost sales.